This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Big win possible for Ionis/Biogen antisense drug in muscular atrophy. Nat Biotechnol 34, 1002–1003 (2016). https://doi.org/10.1038/nbt1016-1002
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1016-1002
This article is cited by
-
How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy
Gene Therapy (2017)
-
Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations
Gene Therapy (2017)
-
The chemical evolution of oligonucleotide therapies of clinical utility
Nature Biotechnology (2017)
-
Spinal muscular atrophy approval boosts antisense drugs
Nature Biotechnology (2017)
-
Nusinersen: First Global Approval
Drugs (2017)